PRS AAPS Oral Proofs 2016
Sanjay Naran, MD, Matthew Miller, BS, Benjamin Ware, BS, Liliana Camison, MD, Jesse Goldstein, MD, Joseph Losee, MD
From the University of Pittsburgh, Pittsburgh, Pa.
PURPOSE: Nonsyndromic craniosynostosis (NSCS) patients are at risk of neurodevelopmental delay. Although many metrics have been analyzed, few have directly examined early language acquisition and speech development. Our purpose was to determine whether infants with NSCS have normal language acquisition and speech development.
METHODS: Patients with NSCS presenting from 2000 to 2014 were queried. Those with identified syndromes were excluded. Data elements included age, gender, Pittsburgh Weighted Speech Score, evaluation for anatomic motor delay, language/speech delay, articulation/phoneme deficiency, hypernasality, velopharyngeal insufficiency or borderline competency, and whether speech therapy was recommended. Diagnosis of a submucous cleft palate (SMCP) was noted. All patients were evaluated by a certified speech and language pathologist.
RESULTS: One hundred sixty-five patients met our criteria. A total of 58.2% were male. Average age at time of most recent speech evaluation was 6.2 years (range, 1.3–17.95). A total of 48.5%% had normal speech/language metrics. A total of 51.5% had 1 or more abnormalities, including anatomic motor delay/disorder (20.6%), speech/language delay (21.2%), articulation/phoneme deficiency (6.1%), hypernasality (12.1%), and velopharyngeal insufficiency or borderline competency (20.0%). A total of 27.9% (n = 31) of patients were recommended to have speech therapy. A total of 17.6% were diagnosed with a SMCP. Of those patients for whom speech/language therapy was prescribed, the average Pittsburgh Weighted Speech Score at most recent follow-up was 2.9 (range, 1–5). Two patients were documented to have global cognitive delay.
CONCLUSIONS: We find that almost 1 in 5 patients with NSCS carry a diagnosis of SMCP. Defective speech and language development necessitating therapy occurred in 1 in 4 patients with NSCS, a prevalence 2 to 3 times higher compared with the general population.